We strive to be a global biopharma leader whose mission is
to develop innovative, life-changing medicine
Pipeline
(Korea's 22nd new drug approval / 1st drug approved by Korean bioventure)
- Tissue-selective COX-2 inhibitor, nonsteroidal anti-inflammatory drug (NSAID)
Acelex® 2mg Capsule / Tablet
구분 | Features |
---|---|
Efficacy
|
|
Dosage
|
|
Gastrointestinal safety
|
|
Cardiovascular safety
|
|


An assessment evaluating the physical function of patients with joint disease.
The Phase 3 clinical study results showed that at 3rd week of treatment the physical function score using WOMAC
was significantly superior compared to placebo.On the other hand, celecoxib did not show statistically significant superiority in this study.


Researchers evaluated using the PGA score, and the patient's improvement is evaluated weekly based on 7 areas.
After the 3rd week of Acelex treatment, the PGA score showed statistically significant superiority compared to celecoxib
-
Exporting to Turkey and
MENA (contract signed) -
Exporting into Brazil
(contract signed) -
Exporting into Eurasian Economic
Community (contract signed)
We are in continous discussion for additional export contracts with a number of promising partners in various other regions
such as the US, Europe, China, Southeast Asia, South America.
Brazil and Russia have submitted an application for market approval.